Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 363

Kleo finds a home at Biohaven

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

Jan 20, 2021

Prostko leaves Comcast to be a Teachers'

Rick Prostko's roster of deals at Comcast included Identified (acquired by Workday), Dollar Shave Club (acquired by Unilever) and Instacart (now valued at $13.7bn).

Jan 20, 2021

Cargill grows with VanLanduit hire

Erin VanLanduit, a GCV Powerlist 2020 award winner during her time at Tyson Foods, is Cargill's new head of corporate ventures.

Jan 19, 2021

Cruise takes in $2bn

Microsoft joined carmakers General Motors and Honda in a round that pushed the driverless car technology developer's valuation to $30bn.

Jan 19, 2021

K Health cages $132m

The Anthem and Comcast-backed remote healthcare provider doubled its valuation for the second time in 10 months, in a series E round valuing it at $1.5bn.

Jan 19, 2021

Everlywell revs up with $75m

HealthQuest Capital supplied $75m for the medical test provider, which counts The Chernin Group as an investor, at a flat $1.3bn valuation.

Jan 19, 2021

Verizon leads Vdoo series B to $57m

Verizon Ventures was among the investors that added $25m to a round already featuring Dell Technologies Capital, MS&AD Ventures and NTT Docomo Ventures.

Jan 19, 2021

BlueSphere Bio brings in series B funding

UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.

Jan 19, 2021

Pignato pulls out of Allied Minds

Allied Minds will henceforth operate without a chief executive after Joseph Pignato announced his decision to resign.

Jan 19, 2021

BlueSphere Bio brings in $45.6m

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Jan 19, 2021
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here